Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. - Wikidata - awgldk - TriplyDB

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

http://www.wikidata.org/entity/Q33882750

about

Dose response of ACE inhibitors: implications of the SECURE trial Influence of diabetes mellitus on heart failure risk and outcome Reducing cardiorenal risk through combination therapy with a direct renin inhibitor Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure?Almanac 2011: Heart Failure. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Difficulties of introducing the National Service Framework for heart failure into general practice in the UK.Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure.Heart failure in the elderly.'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data.Chronic heart failure: contemporary diagnosis and management Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004.Response to Sexton: Inhibiting the renin-angiotensin-aldosterone system in patients with heart failure and renal dysfunction: common sense or nonsense?Effects of low-dose treatment with felodipine versus fosinopril in Chinese patients with nonischemic heart failure and normal blood pressure: A double-blind, randomized, crossover study Epidemiology, aetiology, and prognosis of heart failure.Randomised controlled trial of specialist nurse intervention in heart failure.Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy Quality of congestive heart failure treatment at a Canadian teaching hospital.Radiofrequency catheter ablation of atrial fibrillation initiated by spontaneous ectopic beats.Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients?Practical issues in the treatment of patients with heart failure.The past, present and future of renin-angiotensin aldosterone system inhibition The current cost of heart failure to the National Health Service in the UK.Heart failure in the 21st century: a cardiogeriatric syndrome.Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities.Economics of chronic heart failure.Gender differences in patients with heart failure.Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.Gaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study.Implications of recent heart failure trials for patients with hypertension.Targeting success in heart failure: evidence-based management.Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes.Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.Why we need new strategies in CHF management.Clinical implications of an accurate problem list on heart failure treatment.Use of angiotensin-converting enzyme inhibitor therapy and dose-related outcomes in older adults with new heart failure in the community.

P2860

Q24793271-D567586A-2F9C-4F4E-B192-EA2366085462 Q24800363-706E3336-BF74-4258-834F-4E17150DA403 Q26851307-4E30EBD2-6531-4BBA-866F-F545CA922D2E Q28186417-A304800E-ADD4-4AE4-AB07-B38CB712976B Q28193461-04C1B482-0C76-4766-B148-DC6DF95D379E Q30451215-E85D3A8C-FD81-4CC4-85F2-9C5F6ED842A6 Q30482497-CCB4F025-EEAC-4FD1-BDF1-00B524FC193A Q30851193-05BA7A0C-6A90-4E57-91F0-2B6F8C3F765C Q31119280-72E80AB1-31D0-464C-81DC-9D340CEF036F Q31989723-79C6A0C8-78AC-43D1-9505-98CB579BE4C6 Q32052998-9B46014C-F347-471F-899F-6B2698094A38 Q33196161-9CC6F53E-2C31-4782-B124-2F1E37546CE5 Q33261643-EEF5E4AD-3275-473D-AB9C-55666F3A7761 Q33620431-C76CCC00-B81C-434C-8400-C953E7AB13CC Q33638261-3D93663D-8EBB-4243-84DA-5F75BCA9D8E3 Q33652436-DC94E28D-515E-4A6E-91A1-75072FBE25BE Q33738796-9346466C-76A6-4587-97D0-5F793D34D293 Q33893882-2A39AF88-931A-467F-8CAE-786EDCE57202 Q33942828-003F7E44-EB43-4B23-A555-85FB59F3D677 Q33947702-9571538D-F77A-493C-B80A-FBA96CC932D9 Q33956254-89839923-9C4D-4B3B-92AA-43E36D99CDFE Q34011200-94FB4933-56B4-469C-BCE6-41623362214A Q34027512-EA2885A3-6B93-4103-A0D1-51AFAB748EFF Q34070051-377A66D1-BA0B-46ED-AE23-A409BF7AAF2A Q34088218-A3F791EF-1AC1-4A1A-B0BC-BAABA001E63D Q34094354-9AFF838E-75D9-4679-A216-664B37FAD112 Q34130575-B8A87650-764B-42C1-A6AA-2CA3C1BB5B35 Q34159039-EFE63F0C-10F4-4D18-8CC4-8233AA2E2ED7 Q34193579-81B21BCA-C08D-4331-BACD-AA5B21C2F2A9 Q34264676-62B0A8D8-B17C-4BFB-8EC9-D952F2A1F410 Q34277262-6B0D535C-0E30-4373-822B-A182E16DBBD7 Q34369863-E936A55B-4278-4999-B125-31EE742CE4A8 Q34384769-E0123794-DBBC-4AB8-A9A3-D878E4F263B4 Q34401857-89B9C55E-4984-42E9-9FDA-0DF0D5D71002 Q34406261-D0AC7B5B-7DC9-4DAD-A9AE-2DD08A5966B4 Q34419187-3B14EE67-322E-47FB-91D6-4E8299B1D587 Q34485114-A527F1D3-6EBC-40A3-A65D-B7EE5B517B49 Q34610081-82D27101-DD6B-42BF-B05F-608F2E323C1A Q34722738-3BFFB53B-6ED0-4E34-9FC4-283BAF6F7871 Q34732981-3076C3FE-295E-425B-9A0F-F43FB68491AC

P2860

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

http://www.wikidata.org/entity/Q33882750

description

1999 nî lūn-bûn

@nan

1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Comparative effects of low and ...... rt failure. ATLAS Study Group.

@ast

Comparative effects of low and ...... rt failure. ATLAS Study Group.

@en

type

label

Comparative effects of low and ...... rt failure. ATLAS Study Group.

@ast

Comparative effects of low and ...... rt failure. ATLAS Study Group.

@en

prefLabel

Comparative effects of low and ...... rt failure. ATLAS Study Group.

@ast

Comparative effects of low and ...... rt failure. ATLAS Study Group.

@en

P1433

Q33882750-DCA7F387-4CE2-4D7D-9398-77FC19D1D8FC

P1476

Q33882750-33264D44-C6C9-4251-9E22-02C6BEF145BA

P2093

Q33882750-058EA521-135A-4239-A7DB-4F3484C804C8

Q33882750-5DF76BCB-8C37-4103-90A9-4FFF96E075CB

Q33882750-61824745-B1EA-43FD-9746-4BD259D9CDE2

Q33882750-868EA918-8243-47AC-B4DB-9E06F73F9618

Q33882750-9AB0ECCE-4B94-4107-8DCD-0FC1B0D7C1A4

Q33882750-A916226B-8D2D-4172-AAD8-B3AAF0BDEF03

Q33882750-AA741D3D-B5E4-4126-904B-8B588375F511

Q33882750-C2865CDE-2304-4F88-9486-B8DA98DE6785

P304

Q33882750-54834A0A-58BD-428B-AA9D-5065458C9969

P31

Q33882750-8BB69279-1BA7-4B9F-A2EE-EBA0DDD41333

P356

Q33882750-B9F7AACA-7DF4-4DD9-A962-C612148C4178

P407

Q33882750-5BB43E41-3C9A-464A-B402-68204BCED9DD

P433

Q33882750-D20BC6DD-B26A-487A-B78C-32BD803B016E

P478

Q33882750-30650DA1-A9B9-4224-BE8F-520312704620

P50

Q33882750-CB7CC239-C520-4140-9A4B-93DCF0929639

P577

Q33882750-E282BF93-416B-42EA-B4B9-EFA998AEB9F8

P698

Q33882750-8FC6D222-95AD-4A41-99B9-88CA83DC588C

P921

Q33882750-B86B83C2-1154-4346-A691-3AD2CB2DAAF2

P356

01.CIR.100.23.2312

P1433

P1476

Comparative effects of low and ...... art failure. ATLAS Study Group

@en

P2093

B F Uretsky

http://www.w3.org/2001/XMLSchema#string

B M Massie

http://www.w3.org/2001/XMLSchema#string

J G Cleland

http://www.w3.org/2001/XMLSchema#string

K Thygesen

http://www.w3.org/2001/XMLSchema#string

L Rydén

http://www.w3.org/2001/XMLSchema#string

M Packer

http://www.w3.org/2001/XMLSchema#string

P A Poole-Wilson

http://www.w3.org/2001/XMLSchema#string

P W Armstrong

http://www.w3.org/2001/XMLSchema#string

P304

2312-2318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.100.23.2312

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

P577

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10587334

http://www.w3.org/2001/XMLSchema#string

P921